ArticleResearch square2026
Bioactive dietary polyphenols modulate hippocampal inflammasome activation and sex-specific affective behavioral deficits following peripheral Foxp3
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The transcription factor Foxp3 is the lineage-defining marker essential for the development and suppressive function of regulatory T cells (Tregs), which maintain peripheral immune homeostasis. Emerging evidence suggests that this Foxp3+ Treg axis plays a critical role in modulating central neuroimmune signaling and affective behaviors; however, whether a Bioactive Dietary Polyphenol Preparation (BDPP) can effectively modulate or attenuate these neuroinflammatory responses remains unclear. In this study, we assessed how transient Foxp3 depletion influences affective behaviors, microglial responses, and blood-brain barrier integrity within the hippocampus, and whether BDPP treatment could modulate these outcomes. Foxp3 depletion induced sex-dependent behavioral deficits, characterized by depressive-like behavior, impaired motivational drive, and anxiety-related behavior. These behavioral changes coincided with robust hippocampal Caspase-1 activation and microglial remodeling, as quantified by Sholl analysis, indicating an enhanced inflammasome-associated neuroimmune response following peripheral Treg dysfunction. Notably, BBB integrity was preserved across all groups, demonstrating that peripheral immune dysregulation is sufficient to drive central neuroinflammatory and behavioral abnormalities independent of vascular damage. Furthermore, BDPP administration selectively attenuated these behavioral deficits, caspase-1 activation, and the associated microglial changes predominantly in male subjects, whereas females exhibited limited responsiveness. Collectively, these data establish a functional link between peripheral Treg homeostasis and hippocampal immunity, highlighting BDPP as a sex-specific modulator of immune-driven behavioral dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.